We should no longer view life science, science parks, and innovation districts as real estate projects. Instead, they must be managed as long-term societal investments in knowledge, talent, and the capacity to address complex health challenges.
Success in life science environments should be measured by the ecosystem’s ability to generate research, new companies, and improved healthcare, rather than by the volume of laboratories or office space. Leading regions prioritise expertise, clinical research capacity, digital infrastructure, and shared advanced equipment over occupancy rates. The United Nations Conference on Trade and Development (UNCTAD) emphasises investing equally in programmes, capacity-building, and Intellectual Property expertise alongside buildings and equipment. While science parks have evolved into innovation districts, governance often remains tied to outdated real-estate models.
Effective governance is critical. Without a clear, legitimate, and well-resourced central authority, collaboration fragments into silos, leading to project fatigue. The Global Institute on Innovation Districts (GIID) finds that successful districts have a central actor who sets a unified R&D agenda, drives partnerships, organises infrastructure sharing, and maintains a long-term talent strategy. Governance weakens when new stakeholders introduce differing goals and incentives. To build world-leading environments, it is essential to clarify who sets priorities when universities, regions, municipalities, and private property owners have competing interests.
A shortage of skilled labour remains a major global bottleneck, especially in cell and gene therapies, advanced manufacturing, and data-driven life sciences. Talent is often treated as a secondary HR issue rather than a strategic priority. Investments in facilities and programmes are ineffective without the right people. Leading regions invest in universities and support international recruitment, housing, schools, dual-career solutions, and transitions between academia, healthcare, and industry. Here in Sweden, the current key question is whether talent attraction will receive the same level of priority as investments in new buildings and initiatives under the updated national life science strategy.
Following the pandemic investment wave, the sector faces tighter capital markets, price pressure on pharmaceuticals, and stricter regulations, making short-term project approaches less effective. It must also address ageing populations, chronic diseases, mental illness, and rising healthcare costs. Countries are aligning life science strategies with broader innovation partnerships, that mobilise public and private actors around clear health challenges. Science parks and innovation districts can serve as neutral arenas, if they move beyond local project ownership and act as long-term coordinators of missions extending beyond the next fiscal year.
Life science environments must focus on a few clearly defined areas of excellence as capital, expertise, and trust become more limited. The most competitive regions build strength through targeted investment in talent and infrastructure, supported by governance that resolves conflicts efficiently. For science parks and innovation districts here in Sweden, three key questions remain: which two or three strengths should be recognised internationally, how can a legitimate central authority be organised around them, and will investments in people, programmes, and networks match those in real estate and branding?
Questions like these demand answers, as these environments contribute to global development in multiple tangible ways — not least the economic and reputational gains from generating a significant number of conferences, congresses, and events each year.
